The Intracellular Mechanism of Berberine-Induced Inhibition of CYP3A4 Activity

Author(s): Pan-Feng Feng, Long-Xun Zhu, Jing Jie, Peng-Xiang Yang, Xia Chen*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 40 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Berberine (BBR) is an isoquinoline alkaloid extracted from the Chinese medicine, exerting a variety of pharmacological effects. BBR is partially metabolized by cytochrome 3A4 (CYP3A4) in vivo. Some reports indicated that BBR could inhibit the activity of CYP3A4. However, the underlying mechanisms are not completely understood. CYP3A4 is reported to be transcriptionally regulated by two nuclear receptors, nuclear transcription X receptor (PXR) and constitutive androstane receptor (CAR), and degraded via the ubiquitin-proteasome system. Hence, we tried to explore the mechanisms of CYP3A4 inhibition on both transcriptive and protein levels.

Methods: Western Blot, RT-PCR and Co-immunoprecipitation were used to perform the experiments.

Results: Our results showed that BBR inhibited the transcription of CYP3A4 gene by downregulating PXR. In addition, BBR accelerated the degradation of CYP3A4 protein via polyubiquitination pathway.

Conclusion: These findings may lead to the determination of novel drug-drug interactions with BBR, and contribute to future clinical application of BBR.

Keywords: Berberine, CYP3A4, transcription, ubiquitination degradation, X receptor (PXR), RT-PCR.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 40
Year: 2021
Published on: 15 July, 2021
Page: [4179 - 4185]
Pages: 7
DOI: 10.2174/1381612827666210715155809

Article Metrics

PDF: 30